clinical partnerships

how to apply:

these grants offer funding opportunities for clinicians to validate glycomics data from clinical studies. maximum request: $50,000 for one year.

external deadline:

tuesday, august 31, 2021

url:

https://canadianglycomics.ca/research/call-for-proposals/

agency:

glyconet

funding source:

external

funding level:

research

partnership engage grants

how to apply:

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. however, partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

external deadline:

wednesday, september 15, 2021

url:

https://www.sshrc-crsh.gc.ca/funding-financement/programs-programmes/par...

agency:

social sciences and humanities research council

funding source:

external

funding level:

research

arthur b. mcdonald fellowships

how to apply:

overview

arthur b. mcdonald fellowships recognize early-stage academic researchers in the natural sciences and engineering and support them to enhance their research capacity, so that they can become leaders in their field and inspire others. nserc awards up to six mcdonald fellowships each year.

who can apply?

if you are an early-stage academic researcher, meaning that you have held an independent academic position for 10 years or less as of june 1 of the year of the competition and currently hold a grant from nserc, you can prepare a nomination for this award.

an independent academic position is a position that:

is a university faculty appointment (adjunct, non-tenured or tenured)
requires that the researcher engage in research that is not under the direction of another individual
authorizes the researcher to supervise or co-supervise the research of 世界杯2022赛程表淘汰赛 registered in an undergraduate or graduate degree program, or postdoctoral fellows

a candidate submitting a nomination in june 2021 would have been hired on or after june 1, 2011. the 10-year eligibility window is adjusted to take into account eligible delays in research or periods of inactivity (e.g., due to parental leave, bereavement or illness). for example, a candidate submitting a nomination in june 2021 who took a seven-month parental leave after starting their appointment must have been hired on or after april 1, 2010, in order to be eligible. that is, the eligibility window is increased by two months for every month of eligible delay. for delays related to covid-19, the eligibility window is also increased by two months for every month of delay. you must identify any such periods in the delays in research activity section of your personal data form (form 100), and the impacts of the research delay should be clearly and fully described.

if this award is of interest, please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca for more information.

external deadline:

monday, june 7, 2021

url:

https://www.nserc-crsng.gc.ca/prizes-prix/mcdonald-mcdonald/about-apropo...

award category:

award

agency:

natural sciences and engineering research council

funding source:

external

funding level:

research

team grant : crism phase ii: regional nodes

eligibility:

for a regional node loi to be eligible:

the nominated principal applicant must be an independent researcher.
the nominated principal applicant must be appointed at an eligible institution (see the cihr application administration guide – part 4) within the geographic area covered by the regional node they are leading by the effective date of funding.
the research team must include at least one principal applicant who self-identifies as indigenous (first nations, inuit or métis) and/or demonstrates a track record of meaningful and culturally safe involvement with indigenous peoples. at the full application stage, a one-page document describing how they meet this requirement must be submitted as an “other” attachment (see how to apply section).
at least one project participant must be identified as responsible for directing the methamphetamine use disorder controlled trial within that regional node.
at least one project participant, other than the nominated principal applicant, must be a service provider for problematic substance use, under the broad definition of a knowledge user.
at least one project participant, other than the nominated principal applicant and the service provider, must be a representative from one of these categories: people with lived and living experience, including caregivers, family members, advocacy groups.
the research team must include a sex and gender champion listed as nominated principal applicant, principal applicant or co-applicant. champions are researchers able to meaningfully integrate considerations of sex and gender throughout all aspects of the project design, methods, analysis, implementation and reporting. the sex and gender champion must have successfully completed one of the sex- and gender-based analysis training modules available online through the cihr institute of gender and health and submit a certificate of completion (see how to apply section, regional node full application). please select and complete the training module most applicable to your research project. see additional information for further important information on the champion role.

in addition to meeting the requirements for the loi, for a regional node full application to be eligible:

the full application must have the support of regional or provincial health authorities and/or ministries of health, and (optional) local health units. a minimum of two (2) letters of support are required (with at least one coming from regional or provincial health authorities or ministries of health), but no more than five (5) letters of support in total (see how to apply section).

note: this funding opportunity seeks a minimum of one participant per node who self-identifies as indigenous (first nations, inuit or métis) or provide evidence of having meaningful and culturally safe involvement with indigenous peoples in order to:

prioritize first nations, inuit and métis peoples and communities, including urban indigenous communities, in leading their research agendas;
promote cultural safety of and appropriate engagements by researchers working with indigenous peoples in meaningful ways to ensure that respectful relations* are established;
add value to the research through the use of indigenous culturally relevant theoretical and conceptual frameworks, and indigenous culturally appropriate research protocols, including indigenous methodologies; and
promote equity and development of trainees, researchers and knowledge users who are of indigenous ancestry.

for the controlled trial application to be eligible:

for administrative reason, the nominated principal applicants of each regional node must be a principal applicant on the controlled trial application. one of them should be identified as the nominated principal applicant on the controlled trial application.
participants responsible for directing the methamphetamine use disorder controlled trial within each regional node must be listed as principal applicants (see regional node eligibility criterion 4).
one principal applicant should also be identified as the national coordinator for the controlled trial and be clearly identified as such in the participant table (see how to apply section).
for any research involving first nations, inuit, métis and/or urban indigenous populations, the research team must include at least one principal applicant who self-identifies as indigenous (first nations, inuit or métis) and/or has a track record of meaningful and culturally safe engagement with indigenous peoples. as part of the controlled trial application, a one-page document describing how they meet this requirement must be submitted as an “other” attachment (see how to apply section).

how to apply:

the specific objective of this funding opportunity are to:

provide the base/infrastructure funding to the crism phase ii regional nodes that will allow research teams to organize and collaborate to address critical research in the area of substance use, and to allow them to:
- identify and develop clinical and community-based prevention or treatment interventions and guidelines, including harm reduction, for substance use
- provide evidence to decision makers, providers and stakeholders, to support the enhancement of prevention or treatment services, as well as policy development, regarding substance use
- engage indigenous peoples in canada in research and kt efforts in a manner respecting the rights of indigenous peoples and indigenous self-determination and self-governance, such as following the first nations principles of ocap® (i.e., ownership, control, access and possession)¹, or employing a distinctions-based approach, (see additional information)
- support the improvement in the quality of care and quality of life for canadians with substance use disorder
- involve individuals with lived and living experience throughout the research process
conduct a controlled trial for management of methamphetamine use disorder aligned with the nida ctn

external deadline:

tuesday, june 15, 2021

url:

https://www.researchnet-recherchenet.ca/rnr16/vwopprtntydtls.do?prog=346...

agency:

canadian institutes of health research

funding source:

external

funding level:

research

climate action and awareness fund– advancing climate change science and technology request for proposals

how to apply:

environment and climate change canada’s climate action and awareness fund (caaf) has opened a request for proposals (rfp) for advancing climate change science and technology research.

the rfp will fund up to $59m for projects that will strengthen canada’s science capacity to understand, identify, accelerate, and evaluate actions towards achieving net-zero greenhouse gas emissions by 2050.

to be eligible for funding under this rfp, lead applicants must be one of the following:

not-for-profit non-government organizations (ngo, e.g., environmental community groups),
indigenous organizations, or
universities and academic institutions.

lead applicants are encouraged to develop collaborative proposals and partner with other academic institutions and organizations, including federal, provincial, territorial, or municipal government partners.

there is a two-step application process, consisting of a letter of intent (loi) phase open to all eligible applicants, followed by an invitation-only full proposal phase. the applicant guide and application form are attached, however applications will be accepted only through the grants and contributions enterprise management system. the deadline to submit a loi is june 10, 2021.

the projects funded by this request for proposals must fall under one of the following themes:

theme 1: informing carbon sink enhancements: nature-based climate solutions
theme 2: understanding the potential for, and implications of, negative emission technologies
theme 3: understanding city- and municipal-level ghg emissions and mitigation effectiveness
theme 4: understanding multiple benefits of integrated mitigation approaches for greenhouse gases and air pollutants
theme 5: understanding and quantifying transportation sector emissions in canada

for more information, please visit the climate action and awareness fund webpage.

applications can be submitted to this competition by institutions, not by individuals. if you are interested in applying to this opportunity, please contact andrew hacquoil at ahacquo1@lakeheadu.ca.

external deadline:

thursday, june 10, 2021

url:

https://www.canada.ca/en/services/environment/weather/climatechange/fund...

agency:

environment and climate change canada

funding source:

external

funding level:

research

defense health program department of defense epilepsy research program anticipated funding opportunities for fiscal year 2021 (fy21)

how to apply:

the fy21 defense appropriations act is anticipated to provide funding to the department of defense epilepsy research program (erp) to understand the mechanisms of post-traumatic epilepsy (pte) and associated comorbidities to improve quality of life, especially in service members, veterans, and caregivers. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy21 erp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy21 erp must address one or more of the following focus areas below. an application that proposes research outside of the fy21 focus areas is acceptable, as long as the applicant provides a strong rationale. the focus areas will be mechanism-specific.

innovative research: tools intended to better inform or improve upon how pte research can be performed:

o hardware and/or software platforms that will improve seizure detection, characterization, or diagnosis

o bioinformatics strategies, to include machine learning, that will improve access, annotation, curation, and visualization of large and novel datasets from single or multiple sources

o development of new models or better characterization of existing etiologically relevant models for pte

o characterization of the circuits involved in pte

o validate targets of post-traumatic epileptogenesis or established pte

markers and mechanisms: identifying markers or mechanisms via preclinical models that address pte, which may include the following:

o biomarkers (acute and chronic)

o treatment

o prevention

o comorbidity

epidemiology: epidemiological characterization of pte following traumatic brain injury, which may include the following:

o risk factors such as demographics, genetics, anatomy, pathology, or type of injury

o outcomes including latency to epilepsy, comorbidities, and mortality

o pre-existing conditions including psychological and psychiatric risk factors

o treatment and healthcare outcomes research

o differentiation of pte and psychogenic non-epileptic seizures

longitudinal studies: studies of the evolution of pte, which may include the following:

o seizure frequency and semiology

o demographics, genetics, anatomy, pathology, or type of injury

o comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)

o latency between type of injury and pte

o mortality

o treatment outcome and healthcare outcome research

quality of life: understanding and improving the quality of life for individuals with pte and their caregivers by addressing the following:

o psychosocial factors

o neuropsychological dysfunction (cognition and memory)

o behavioral health (anxiety, depression, post-traumatic stress disorder, impulsivity)

o reducing stigma

o activities of daily living

o reducing healthcare disparities (adjunct programs, support groups, access to care)

o sleep disorders

o medication side effects

https://cdmrp.army.mil/funding/erp

idea development award – letter of intent due june 14, 2021

level i: investigators at or above the level of postdoctoral fellow (e.g., research associates, fellows, medical residents, or equivalent) but below the level of assistant professor (or equivalent) at the time of the application submission deadline.

• mentor(s) required.

level ii: the principal investigator (pi) must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

intent: to solicit novel, innovative research to understand the magnitude and underlying mechanisms of post-traumatic epilepsy (pte).

• level i: applicants can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the mentor(s). the mentor(s) must possess qualifications, background, and experience in pte research.

• level ii is intended to support a more mature, hypothesis-driven research project. applicants can be from any field or discipline.

applicants should select one of the focus areas below:

• innovative research

• markers and mechanisms

• epidemiology

• longitudinal studies

while not required, applications to either funding level i or ii are encouraged to provide relevant preliminary data.

clinical pharmacologic trials are specifically discouraged.

level i:

• maximum funding of $300,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s rate agreement.

level ii:

• maximum funding of $500,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s rate agreement.

quality of life award – letter of intent due june 14, 2021

• mentor(s) required.

level ii: the pi must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

intent: to support research that better understands or improves the quality of life and care for individuals living with the symptoms of pte, as related to the erp’s mission.

• level ii is intended to support a more mature, hypothesis-driven research project. applicants can be from any field or discipline.

the following focus area must be addressed as part of the application:

• quality of life

an application that proposes research outside of this focus area will be withdrawn.

while not required, applications to either funding level i or ii are encouraged to provide relevant preliminary data.

clinical pharmacologic trials are specifically discouraged.

animal research is prohibited.

level i:

• maximum funding of $300,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s rate agreement.

level ii:

• maximum funding of $500,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s rate agreement.

research partnership award – letter of intent due june 14, 201

the initiating pi must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

each named co-pi must be at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

intent: to create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.

level i is intended to support preclinical or pre-validation research.

level ii is intended to support research that requires access to a patient cohort for a prospective study and must be the focus of the application.

applications must include clearly stated plans for interactions between/among the partners. the plans must include communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among all investigators and organizations participating in the project.

applicants should select one of the focus areas below:

• markers and mechanisms (funding level i only)

• epidemiology (funding level i only)

• longitudinal studies (funding level ii only)

clinical pharmacologic trials are specifically discouraged.

preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are required.

level i:

• maximum funding of $1,300,000 in total costs.

• maximum period of performance is 3 years.

• indirect costs may be proposed in accordance with the institution’s rate agreement.

level ii:

• maximum funding of $3,100,000 in total costs

• maximum period of performance is 4 years.

• indirect costs may be proposed in accordance with the institution’s rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the erp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

external deadline:

monday, june 14, 2021

url:

https://cdmrp.army.mil/funding/erp

agency:

department of defense

funding source:

external

funding level:

research

wintertech development program

eligibility:

best suited for:

applicant:

small- or medium-sized enterprise (sme) 
required to have operations in ontario
companies who have received over $500,000 of oci funding in their lifetime (excluding talentedge) are required to obtain oci approval before a new application for funding is initiated. your business development manager can guide you through the process.

partners:

for-profit small and medium-sized enterprises (smes)
for-profit national and multi-national enterprises (nes and mnes)
publicly-funded post-secondary academic institutions (secondary)
municipalities
indigenous communities
not-for-profit organizations
required to have operations and carry out projects in ontario

how to apply:

the autonomous vehicle innovation network (avin)’s wintertech development program will support ontario smes in the mobility space and their partners to validate, test, prototype and demonstrate new products and technologies designed to meet the unique demands of winter weather conditions. wintertech will leverage the strengths and innovative capabilities of ontario smes in the mobility space and our unique winter weather conditions to establish the province as a testbed for mobility products and services in severe winter weather conditions. through avin’s wintertech development program, ontario is a global leader in the commercialization of new winter-ready mobility technologies and solutions.

external deadline:

wednesday, may 19, 2021

url:

https://www.oc-innovation.ca/programs/autonomous-vehicle-innovation-netw...

agency:

ontario centres of excellence

funding source:

external

funding level:

research

av research and development (r&d) partnership fund stream 2 – technology demonstration projects

eligibility:

eligibility requirements applicants

• an applicant is an sme (generally defined as having fewer than 500 full-time employees)

• an sme may be an applicant on only one av r&d partnership fund or wintertech development program project at a time.

• must have operations (r&d, manufacturing, product management, etc.) in ontario

• companies who have received over $500,000 of oci funding in their lifetime (excluding talentedge) are required to obtain oci approval before a new application for funding is initiated. your business development manager can guide you through the process.

partners

• small and medium-sized enterprises (smes)

o smes may be primary or secondary partners on multiple concurrent projects.

• national and multi-national enterprises (nes and mnes)

o nes and mnes can be primary or secondary partners on multiple concurrent projects.

• publicly-funded post-secondary academic institutions (as secondary partners only)

• municipalities

• indigenous communities

• not-for-profit organizations

how to apply:

the av r&d partnership fund (stream 2) contributes up to one-third of eligible project costs for approved projects up to a maximum of $1,000,000, with the remainder contributed by applicants and/or partners. project funding can be used towards the development and demonstration of technologies in the connected and autonomous vehicle (cav) sector, in the following priority areas:

• mass light vehicles (e.g., cars, trucks and vans)

• heavy duty vehicles (including commercial vehicles, trucks, buses, rvs and others used for goods movement)

• transportation infrastructure

• intelligent transportation systems (its)

• transit-supportive systems and vehicles

external deadline:

wednesday, may 19, 2021

url:

https://www.oc-innovation.ca/programs/autonomous-vehicle-innovation-netw...

agency:

ontario centres of excellence

funding source:

external

funding level:

research

defense health program department of defense peer reviewed alzheimer’s research program anticipated funding opportunities for fiscal year 2021 (fy21)

how to apply:

he fy21 defense appropriations act is anticipated to provide funding to the department of defense prarp to support research that addresses the long-term implications of military service as they pertain to alzheimer’s disease (ad) and related dementias (adrd) for service members, veterans, and the general public. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy21 prarp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy21 prarp program announcements must address one of the following fy21 overarching challenges, which may be award mechanism-specific:

prarp fy21 overarching challenges
foundational research: research to examine the interrelationship between military service-related risk factors and subsequent ad/adrd
paucity of clinical studies: the paucity of clinical studies to examine the interrelationship between military service-related risk factors and subsequent ad/adrd
diagnostics and prognostics: the need for technologies, tests, surveys, questionnaires, devices, biomarkers, or analyses to detect the relationship between military service-related risk factors and ad/adrd
epidemiology: the need for epidemiological research to examine the interrelationship between military service, risk and resiliency factors, and subsequent ad/adrd
quality of life: the need for technologies, assessments, interventions, or devices to benefit individuals, especially affected service members and veterans, living with the symptoms of ad/adrd
family and care support: the need for technologies, assessments, interventions, or devices that enhance the lives of those providing care to those living with the symptoms of ad/adrd, especially affected service members and veterans

in addition to addressing one of the specified fy21 overarching challenges, applications must also address one or more of the following fy21 military risk factors in support of the fy21 overarching challenges.

the prarp fy21 military risk factors are listed below.

prarp fy21 military risk factors

traumatic brain injury: studies investigating how head injuries function as risk factors for subsequent ad/adrd

neuropsychological/neurobehavioral: alterations in cognition or behavior that may be associated with subsequent ad/adrd

modifiable risk factors: alterations in activities (e.g., exercise, diet, behaviors, etc.) that may be associated with subsequent ad/adrd

vascular: studies investigating the vascular (e.g., heart disease, hypertension, hyperlipidemia) contributions to cognitive impairment and dementia risk factors for subsequent ad/adrd

inflammation: evaluating the pathways of peripheral and brain inflammation and its relationship to subsequent ad/adrd

genetic: genomic analyses or genetic manipulations that investigate the linkages with subsequent ad/adrd

metabolic: alterations in bioenergetics (e.g., diabetes, brain metabolism, endocrine dysfunction) that may be associated with subsequent ad/adrd

sleep: alterations in sleep patterns (e.g., physiological changes or glymphatic changes) that may be associated with subsequent ad/adrd

the following is a summary of the fy21 prarp program announcements. five award mechanisms will be offered for fy21.

https://cdmrp.army.mil/funding/prarp

convergence science research award (csra) – letter of intent due june 14, 2021

level i: investigators at the postdoctoral level (e.g., research associates, fellows, medical residents, or equivalent) but below the level of assistant professor (or equivalent) at the time of the application submission deadline.

 mentor required.

level ii: the principal investigator (pi) must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

intent: to support innovative and impactful efforts to generate research resources, tools, and new avenues of investigation for researchers and practitioners in the health sciences.

 level i: applicant can be from any field or discipline and must write the project narrative and other application components, with appropriate guidance from the mentor(s). the mentor(s) must possess qualifications, background, and experience in both the identified military risk factor and alzheimer’s disease (ad)/ad-related dementias (adrd) research.

 level ii: intended to support applicants from any field or discipline at or above the level of assistant professor (or equivalent) from any field or discipline. study teams are expected to demonstrate relevant experience in both the identified military risk factor and ad/adrd.

applications must address one of the following fy21 prarp overarching challenges:

 foundational research

 paucity of clinical studies

 diagnostics and prognostics

 epidemiology

applications should address one of the following fy21 prarp military risk factors:

 traumatic brain injury

 neurophysiological/neurobehavioral

 vascular

 inflammation

 genetic

metabolic

 sleep

pharmacological interventions are specifically discouraged.

while not required, applications to either funding level i or ii are encouraged to provide relevant preliminary data.

research that focuses exclusively on chronic traumatic encephalopathy (cte) research is prohibited.

pharmacological interventions are specifically discouraged.

chronic traumatic encephalopathy (cte) research is prohibited.

preliminary data, while not required, are encouraged.

level i:

 maximum funding of $225,000 for direct costs (plus indirect costs).

 maximum period of performance is 3 years.

level ii:

 maximum funding of $500,000 for direct costs (plus indirect costs).

 maximum period of performance is 3 years.

for both levels:

indirect costs may be proposed in accordance with the institution’s rate agreement.

innovation in care and support award (incasa) – letter of intent due june 14, 2021

 mentor required.

level ii: the pi must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

intent: to support innovative and impactful research that improves the quality of life and care for individuals, families, and care providers living with ad/adrd.

applications must address one of the following fy21 prarp overarching challenges:

 paucity of clinical studies

 quality of life

 family and care support

applications should address one of the following fy21 prarp military risk factors:

 traumatic brain injury

 neurophysiological/neurobehavioral

 modifiable risk factors

 vascular

 inflammation

 genetic

 metabolic

 sleep

pharmacological interventions are specifically discouraged.

animal research is prohibited.

while not required, applications to either funding level i or ii are encouraged to provide relevant preliminary data.

research that focuses exclusively on cte research is prohibited.

level i:

 maximum funding of $225,000 for direct costs (plus indirect costs).

 maximum period of performance is 3 years.

level ii:

 maximum funding of $500,000 for direct costs (plus indirect costs).

 maximum period of performance is 3 years.

for both levels:

indirect costs may be proposed in accordance with the institution’s rate agreement.

research partnership award (rpa) – letter of intent due june 14, 2021

the initiating pi must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

each named co-pi must be at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

applications must address one of the following fy21 prarp overarching challenges:

 foundational research

 paucity of clinical studies

 diagnostics and prognostics

 epidemiology

 quality of life

 family and care support

applications should address at least one of the following fy21 prarp military risk factors:

 traumatic brain injury

 neurophysiological/neurobehavioral

 modifiable risk factors

 vascular

 inflammation

 genetic

 metabolic

 sleep

pharmacological interventions are specifically discouraged.

preliminary data to support the feasibility of the research hypothesis (or hypotheses) or objectives are required.

research that focuses exclusively on cte research is prohibited.

funding limit is $1.3 million (m) in total costs.

 maximum period of performance is 3 years.

 indirect costs may be proposed in accordance with the institution’s rate agreement.

accelerating diagnostics research award (adra) – letter of intent due june 14, 2021

the pi must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

intent: to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to ad/adrd.

applications must address the following fy21 prarp overarching challenge.

 diagnostics and prognostics

applications must address one of the following fy21 prarp military risk factors:

 traumatic brain injury

 neurophysiological/neurobehavioral

 vascular

 inflammation

 genetic

 metabolic

the proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to the proposed military risk factor and ad/adrd. the applicant must choose one biomarker category for the overall application:

 imaging-related

 fluid-based (e.g., cerebrospinal fluid, blood, or saliva)

 retinal

 wearable devices

 other

studies focused on biomarker discovery are discouraged.

pharmacological interventions are specifically discouraged.

animal research is prohibited.

preliminary data regarding the suitability of the biomarker(s) for further testing toward biomarker qualification is required.

research that focuses exclusively on cte research is prohibited.

funding limit is $2.8m in total costs.

 maximum period of performance is 4 years.

 indirect costs may be proposed in accordance with the institution’s rate agreement.

leveraging approaches for innovation in care and support award (leap-incasa) – letter of intent due june 14, 2021

the pi must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.

intent: to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to ad/adrd.

applications must address the following fy21 prarp overarching challenge.

 diagnostics and prognostics

applications must address one of the following fy21 prarp military risk factors:

 traumatic brain injury

 neurophysiological/neurobehavioral

 vascular

 inflammation

 genetic

 metabolic

 imaging-related

 fluid-based (e.g., cerebrospinal fluid, blood, or saliva)

 retinal

 wearable devices

 other

studies focused on biomarker discovery are discouraged.

pharmacological interventions are specifically discouraged.

animal research is prohibited.

preliminary data regarding the suitability of the biomarker(s) for further testing toward biomarker qualification is required.

research that focuses exclusively on cte research is prohibited.

funding limit is $2.8m in total costs.

 maximum period of performance is 4 years.

 indirect costs may be proposed in accordance with the institution’s rate agreement.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the prarp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

external deadline:

monday, june 14, 2021

url:

https://cdmrp.army.mil/funding/prarp

agency:

department of defense

funding source:

external

funding level:

research

sharcnet dedicated programming support: round xviii call for proposals

eligibility:

the programme is open to all faculty holding a valid compute canada account. in the event that proposals are closely ranked, preference will be given to faculty from sharcnet partner institutions.

how to apply:

on april 9, 2021 sharcnet issued a call for proposals for dedicated programming support round xviii. applications are encouraged that satisfy the programme objectives and priority will be given to proposals that meet one or more of the following conditions:

propose an innovative project that will leverage the capabilities of the national systems, such as “graham” and the cloud.
propose a programme of work that deals with the efficient processing of large, heterogeneous datasets using a variety of data mining, machine learning or other analytics software.

applications are submitted via sharcnet’s webportal and are due by may 21, 2021 at 11:59 pm est. please note that consultation with a sharcnet hptc prior to submission is a programme requirement.

due to the current workload of sharcnet programming staff, only a limited number of proposals are expected to be awarded in this round. for additional information, please refer to the application guidelines. questions should be addressed to research-support@sharcnet.ca.

external deadline:

friday, may 21, 2021

url:

https://www.sharcnet.ca/documents-public/prog_guide_apr2021.pdf

agency:

sharcnet

funding source:

external

funding level:

research